Relative Bioavailability and Food Effect Study in Healthy Subjects Administered Two Different Formulations of LY3202626
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs LY 3202626 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 19 Jun 2017 Status changed from recruiting to completed.
- 24 Feb 2017 Planned End Date changed from 1 Mar 2017 to 4 Apr 2017.
- 24 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 4 Apr 2017.